Published: September 30, 2026
For decades, biomedical researchers have relied on animal models to evaluate the safety and efficacy of new pharmaceuticals. However, this biological proxy system is notoriously inefficient, with over 90 percent of clinical drug candidates failing during human trials despite showing promise in preclinical animal testing. To address this biological translation gap, a multidisciplinary convergence of microfluidics, embedded systems, and material science is giving rise to a powerful alternative: Organ-on-a-Chip (OoC) technology.
Often referred to as New Approach Methodologies (NAMs), these biomimetic systems are shifting drug discovery away from traditional animal models. For electronics engineers, roboticists, and embedded developers, these platforms represent an incredible engineering feat—effectively transforming organic biology into standardized, modular hardware systems.



